Search results for Canakinumab ELISA Kit
Canakinumab ELISA Kit, ProteoGenix, KPTX131
Description of Canakinumab ELISA Kit Canakinumab ELISA Kit: A Comprehensive Guide Introduction Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), a pro-inflammatory cytokine involved in various inflammatory diseases. It is primarily used as a therapeutic agent for the treatment of rare auto-inflammatory disorders such as cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (SJIA). The development of a Canakinumab ELISA kit has greatly facilitated the detection and quantification of this important therapeutic target. Structure of Canakinumab Canakinumab is a fully human IgG1 monoclonal antibody with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Canakinumab specifically binds to IL-1β, preventing its interaction with its receptor and inhibiting its pro-inflammatory effects. ELISA Principle ELISA (enzyme-linked immunosorbent assay) is a widely used technique for the detection and quantification of various molecules, including antibodies and antigens. The Canakinumab ELISA kit utilizes the principle of sandwich ELISA, where the target molecule is captured between two specific antibodies. In this case, the IL-1β present in the sample is captured by the Canakinumab-coated plate and detected by a secondary antibody conjugated with an enzyme. The resulting color change is then measured and is proportional to the amount of IL-1β present in the sample. Application of Canakinumab ELISA Kit The Canakinumab ELISA kit has a wide range of applications in both research and clinical settings. It is primarily used for the quantification of Canakinumab levels in patient samples, allowing for the monitoring of drug efficacy and dosing optimization. Additionally, it can also be used to measure IL-1β levels in various biological samples, providing valuable insights into the inflammatory status of a patient. Monitoring Canakinumab Therapy Canakinumab ELISA kit is an essential tool for monitoring the efficacy of Canakinumab therapy in patients with CAPS and SJIA. By measuring the levels of Canakinumab in the blood, clinicians can determine if the drug is reaching therapeutic levels and adjust the dosage accordingly. This helps in optimizing treatment and ensuring better patient outcomes. Assessment of Inflammatory Disorders IL-1β is a key mediator of inflammation, and its levels are often elevated in various inflammatory disorders. Canakinumab ELISA kit can be used to measure IL-1β levels in biological samples, providing valuable information about the inflammatory status of a patient. This can aid in the diagnosis and monitoring of diseases such as rheumatoid arthritis, gout, and atherosclerosis. Research Applications The Canakinumab ELISA kit is also widely used in research studies to investigate the role of IL-1β in various diseases and to evaluate the efficacy of new anti-inflammatory therapies. It enables researchers to accurately measure Canakinumab levels in different biological samples, providing valuable insights into the mechanism of action of this therapeutic antibody. Conclusion The Canakinumab ELISA kit is an essential tool for the detection and quantification of Canakinumab and IL-1β in various biological samples. It has revolutionized the monitoring of Canakinumab therapy and has enabled researchers to gain a better understanding of the role of IL-1β in inflammatory diseases. With its high sensitivity and specificity, the Canakinumab ELISA kit is a valuable asset in the field of immunology and inflammation research.
Host
Reactivity
Applications
Conjugation
Canakinumab ELISA Kit, Abbexa, abx395020
Canakinumab ELISA Kit is a quantitative ELISA kit for detection of Canakinumab.Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by Novartis. its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of familial cold auto-inflammatory syndrome and Muckle-wells syndrome, which are inflammatory diseases related to cryopyrin-associated periodic syndromes. The drug is currently being evaluated for its potential in the treatment of rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, chronic obstructive pulmonary disease, type 1 and 2 diabetes and ocular diseases. Reports from clinical trials suggest that canakinumab is well-tolerated in most patients, and no serious adverse effects have been reported. The drug provides significant advantages over existing competitive therapies, including bimonthly administration and approved use in children.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.